TRT does not appear to consistently worsen benign prostatic hyperplasia (BPH) or urinary symptoms in every man when it is appropriately prescribed and monitored. However, testosterone does interact with prostate tissue, so prostate and urinary health remain important considerations during treatment.
For men receiving testosterone replacement therapy (TRT) in Canada, symptoms such as weak urine flow, urgency, frequent urination or waking often at night to urinate should be reviewed in context. These symptoms may be related to BPH, but they can also have other causes.
New or worsening urinary symptoms after starting TRT should not automatically be blamed on testosterone. A healthcare provider can assess whether the change is related to prostate enlargement, another urinary condition or a separate health issue that needs attention.
Topics covered in this article:
Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland that becomes more common as men get older. It is one of the most common causes of lower urinary tract symptoms in middle-aged and older men.
The prostate sits below the bladder and surrounds part of the urethra, the tube that carries urine out of the body. As the prostate enlarges, it can press on the urethra or affect how the bladder empties.
This may lead to urinary symptoms such as:
BPH is not prostate cancer, and having an enlarged prostate does not mean cancer is present. However, BPH, prostate cancer and other urinary conditions can sometimes cause similar symptoms, so persistent changes in urination should be properly assessed.
For men considering or already using TRT, understanding whether urinary symptoms are related to existing BPH is important because prostate enlargement can progress with age independently of testosterone treatment.
An enlarged prostate can cause urinary symptoms when it affects urine flow or bladder emptying. These symptoms are often grouped under the term lower urinary tract symptoms (LUTS).
Common symptoms of BPH include:
The severity of urinary symptoms does not always match prostate size. A man with a significantly enlarged prostate may have relatively mild symptoms, while someone with a smaller prostate may still experience bothersome urinary problems.
This is why BPH is assessed based on both prostate health and the actual symptoms a man is experiencing, rather than prostate size alone.
Not necessarily. Current research does not show that appropriately prescribed TRT consistently worsens BPH or lower urinary tract symptoms in men with testosterone deficiency.
Studies comparing testosterone therapy with placebo have generally found little or no meaningful worsening in symptoms such as weak urine flow, urinary frequency, urgency or nighttime urination. Some research has even reported stable urinary symptoms despite ongoing testosterone treatment.
That does not mean TRT should be considered a treatment for BPH. Testosterone and prostate health are still closely connected, and urinary symptoms can change for many reasons as men age.
Men with significant lower urinary tract symptoms, such as severe difficulty urinating, poor bladder emptying or very weak urine flow, should be assessed before starting or continuing TRT. Severe symptoms may require further prostate or urological evaluation.
If BPH symptoms worsen after starting TRT, the change should be investigated rather than automatically assuming testosterone is responsible.
TRT may cause a small increase in prostate volume in some men, especially when testosterone rises from very low levels back toward the normal physiologic range. However, this does not necessarily mean BPH will worsen or urinary symptoms will become more severe.
Prostate tissue is androgen-sensitive, which means it responds to hormones such as testosterone and dihydrotestosterone. When testosterone deficiency is corrected, some prostate growth may occur as the tissue returns toward its expected hormone-supported state.
The important distinction is between a small change in prostate size and clinically meaningful progression of BPH. A modest increase in prostate volume does not automatically lead to weaker urine flow, urinary retention or more frequent urination.
Prostate size and urinary symptoms do not always move together. Some men with larger prostates have mild symptoms, while others with smaller prostates can have significant lower urinary tract symptoms.
For that reason, men on TRT should be monitored based on both prostate health and actual urinary symptoms rather than prostate size alone.
Often, yes. Having benign prostatic hyperplasia (BPH) does not automatically make someone ineligible for TRT. What matters more is the severity of urinary symptoms, overall prostate health and whether any concerns have been properly assessed.
Before starting or continuing TRT, a healthcare provider may review:
Men with mild or stable BPH may still be candidates for TRT when testosterone deficiency is appropriately diagnosed. However, severe lower urinary tract symptoms may need further evaluation before treatment begins or continues.
The decision should be individualized. BPH, PSA results, urinary symptoms and testosterone deficiency should be considered together rather than treating an enlarged prostate as an automatic reason to avoid TRT.
Urinating more after starting TRT does not necessarily mean testosterone is the cause. Increased urinary frequency can have several explanations, especially in men over 40.
Possible causes include:
Because several conditions can cause the same symptom, persistent urinary frequency after starting TRT should be assessed rather than automatically attributed to testosterone.
A healthcare provider may review when the symptom started, whether it occurs mainly during the day or at night, and whether there are other signs such as weak urine flow, burning, incomplete emptying or increased thirst.
TRT does not appear to predictably worsen urine flow in every man, but changes in urination should still be assessed, especially in those with existing BPH.
A weak or slow urine stream can happen when an enlarged prostate narrows the urethra and creates bladder outlet obstruction. This can make it harder to start urinating, reduce flow strength or leave a feeling that the bladder has not fully emptied.
Current evidence does not show that appropriately prescribed TRT consistently worsens these symptoms in all men. However, BPH can progress with age independently of testosterone treatment.
If urine flow becomes noticeably weaker after starting TRT, it should not automatically be blamed on testosterone. A healthcare provider may assess prostate enlargement, bladder emptying, urinary retention, infection or other possible causes before deciding whether any treatment changes are needed.
Frequent nighttime urination, known as nocturia, can occur in men on TRT, but it does not necessarily mean testosterone is the cause. Nocturia has many possible explanations, especially in men over 40.
Common contributors include:
If nocturia begins or worsens after starting TRT, the timing alone does not prove that testosterone caused it. A healthcare provider may review prostate symptoms, sleep quality, blood sugar, medications and other possible causes before deciding whether TRT is contributing.
BPH and low testosterone often occur in the same age group, but one does not necessarily cause the other. Both become more common as men get older, especially after age 40.
Metabolic factors may also connect the two conditions. Obesity, insulin resistance, type 2 diabetes and metabolic syndrome are associated with both lower testosterone levels and a higher likelihood of urinary symptoms or BPH.
However, an association does not prove direct causation. Having low testosterone does not automatically mean a man will develop an enlarged prostate, and having BPH does not mean testosterone levels are low.
The symptoms should therefore be assessed separately. Low testosterone may cause reduced libido, fatigue or fewer spontaneous erections, while BPH more commonly causes weak urine flow, urgency, frequent urination or nocturia.
A healthcare provider can evaluate both conditions independently and determine whether one, both or another health issue is contributing to the symptoms.
Yes. Benign prostatic hyperplasia (BPH) can raise PSA levels because a larger prostate contains more tissue that produces prostate-specific antigen.
However, BPH is only one possible reason for a higher PSA. Levels can also rise because of prostate inflammation, infection, recent ejaculation, urinary procedures or other prostate conditions.
An elevated PSA does not mean prostate cancer is present, and BPH itself is not prostate cancer.
If PSA rises during TRT, the result should be interpreted alongside previous values, symptoms and overall prostate risk. For more detail, see our article on PSA levels during TRT.
TRT may cause a modest change in PSA in some men with BPH, but an increase should not automatically be blamed on testosterone or prostate enlargement.
Men with BPH may already have a higher baseline PSA because a larger prostate contains more PSA-producing tissue. After TRT begins, some men may experience a small increase, while others have little or no meaningful change.
What matters most is the baseline PSA and the trend over time. A significant or persistent rise should be assessed in the context of age, urinary symptoms, prostate history and other risk factors.
For detailed guidance on PSA changes, testing and monitoring during treatment, see our article on PSA levels during TRT.
No. Benign prostatic hyperplasia (BPH) and prostate cancer are different conditions, and having an enlarged prostate does not mean you have prostate cancer.
BPH is a non-cancerous growth of prostate tissue that becomes increasingly common with age. Prostate cancer involves abnormal cancerous cell growth. The two conditions can occur at the same time, but one does not automatically indicate the other.
They can also cause some overlapping urinary symptoms, such as a weak urine stream, difficulty urinating or frequent urination. Symptoms alone cannot distinguish BPH from prostate cancer, which is why persistent or concerning changes should be medically assessed.
For a more detailed discussion, see our article on TRT and prostate cancer risk.
Yes. Prostate and urinary health should be reviewed before starting TRT when clinically appropriate, particularly in middle-aged and older men. Guidelines recommend considering prostate cancer risk and significant lower urinary tract symptoms as part of the pretreatment assessment.
A healthcare provider may review:
Significant or unexplained urinary symptoms should generally be investigated rather than assumed to be normal BPH. Canadian guidance on BPH also recommends evaluating urinary symptoms systematically to identify their likely cause and severity.
For men with substantial prostate or urinary concerns, the decision to start TRT should be individualized after discussing potential benefits, uncertainties and appropriate monitoring with a healthcare provider.
Urinary symptoms are usually monitored by establishing a baseline before TRT and watching for meaningful changes after treatment begins.
A healthcare provider may ask about:
If these symptoms become noticeably worse during TRT, further assessment may be appropriate to determine whether BPH, another urinary condition or another health issue is contributing.
PSA testing and other prostate monitoring may also be recommended when clinically appropriate based on age, prostate history and individual risk.
Monitoring should be individualized. Not every man needs the same testing schedule, but new or worsening urinary symptoms should be reviewed rather than assumed to be a normal effect of TRT.
Worsening urinary symptoms during TRT should be assessed, but they should not automatically be blamed on testosterone.
A healthcare provider may consider:
Symptoms such as weaker urine flow, increasing frequency, urgency, difficulty emptying the bladder or worsening nocturia may require further prostate or urological assessment.
The goal is to identify the cause before deciding whether TRT needs to be adjusted, continued or temporarily reconsidered.
Not automatically. Worsening BPH symptoms do not always mean TRT needs to be stopped.
Mild urinary symptoms may sometimes be managed while TRT continues, depending on their cause and severity. More significant symptoms, such as a markedly weaker urine stream, difficulty emptying the bladder or worsening urinary retention, should be clinically assessed.
The priority is to determine why the symptoms changed. BPH progression, infection, bladder problems, medications or other health conditions may be contributing rather than TRT itself.
Any decision to continue, adjust or temporarily stop TRT should be individualized based on urinary symptoms, prostate health and the overall treatment plan.
Do not stop or change TRT on your own. Treatment changes should be made with a healthcare provider.
BPH and urinary symptoms can often be managed with lifestyle changes, treatment of contributing factors and clinician-guided care when needed. The right approach depends on how severe the symptoms are and what is causing them.
Helpful measures may include:
If symptoms are persistent or bothersome, a healthcare provider may recommend BPH-specific treatment based on prostate size, symptom severity, bladder emptying and overall health.
Management should focus on the underlying cause rather than assuming TRT is responsible. Men with significant difficulty urinating, urinary retention or rapidly worsening symptoms may need further prostate or urological assessment.
Speak to a healthcare provider if urinary symptoms are new, persistent or getting worse during TRT.
Symptoms that should be assessed include:
An inability to urinate requires urgent medical assessment.
These symptoms may be related to BPH, but infection, bladder problems, urinary retention or other conditions may also be responsible.
Do not stop, reduce or otherwise change TRT on your own. Any treatment changes should be made with a healthcare provider after the cause of the urinary symptoms has been assessed.
TRT may cause a small increase in prostate volume in some men, particularly when testosterone rises from very low levels into the normal range. This does not necessarily mean BPH symptoms will worsen.
Not necessarily. Current evidence does not show that appropriately prescribed TRT consistently worsens BPH or lower urinary tract symptoms in men with testosterone deficiency.
Often, yes. BPH alone does not automatically make someone ineligible for TRT. The severity of urinary symptoms and overall prostate health should be considered.
Increased urination after starting TRT does not prove testosterone is the cause. BPH, diabetes, increased fluid intake, medications, bladder conditions and urinary infections can also increase urinary frequency.
Not necessarily. Nighttime urination, or nocturia, can result from BPH, sleep apnea, diabetes, evening fluid or alcohol intake, medications and bladder conditions.
TRT does not predictably weaken urine flow in every man. A weaker stream may be related to BPH progression, bladder outlet obstruction or another urinary problem and should be assessed if it persists.
Testosterone can influence prostate tissue, and a modest increase in prostate volume may occur in some men receiving TRT. Prostate size, however, does not always correspond with the severity of urinary symptoms.
Yes. BPH can increase PSA because a larger prostate contains more PSA-producing tissue. PSA changes during TRT should be interpreted based on baseline levels, trends and individual prostate risk.
Not every man with BPH needs treatment before TRT. Mild or stable symptoms may not prevent treatment, while significant or unresolved urinary symptoms should be assessed first.
Not automatically. The cause and severity of the symptoms should be evaluated before deciding whether TRT needs to be adjusted or stopped.
Low testosterone and urinary symptoms are associated in some men, particularly as they age and develop metabolic health problems. However, low testosterone does not necessarily directly cause BPH or urinary symptoms.
New, persistent or worsening symptoms such as weak urine flow, difficulty urinating, frequent urination, nocturia, pain, blood in the urine or incomplete bladder emptying should be discussed with a healthcare provider. An inability to urinate requires urgent medical assessment.